Cargando…
Ketoglutaric acid can reprogram the immunophenotype of triple-negative breast cancer after radiotherapy and improve the therapeutic effect of anti-PD-L1
BACKGROUND: Great progress has been made in applying immunotherapy to the clinical treatment of tumors. However, many patients with triple-negative breast cancer (TNBC) cannot benefit from immunotherapy due to the immune desert type of TNBC, which is unresponsive to immunotherapy. DMKG, a cell-perme...
Autores principales: | Tan, Hongpei, Liu, Jiahao, Huang, Jing, Li, Yanan, Xie, Qiongxuan, Dong, Yuqian, Mi, Ze, Ma, Xiaoqian, Rong, Pengfei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10337087/ https://www.ncbi.nlm.nih.gov/pubmed/37438720 http://dx.doi.org/10.1186/s12967-023-04312-2 |
Ejemplares similares
-
PCMT1 is a potential target related to tumor progression and immune infiltration in liver cancer
por: Liu, Jiahao, et al.
Publicado: (2023) -
Preoperative Body Composition Combined with Tumor Metabolism Analysis by PET/CT Is Associated with Disease-Free Survival in Patients with NSCLC
por: Tan, Hongpei, et al.
Publicado: (2022) -
Salmonella-mediated blood‒brain barrier penetration, tumor homing and tumor microenvironment regulation for enhanced chemo/bacterial glioma therapy
por: Mi, Ze, et al.
Publicado: (2023) -
Controversial role of ILC3s in intestinal diseases: A novelty perspective on immunotherapy
por: Zhang, Yunshu, et al.
Publicado: (2023) -
Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancer
por: Hammerl, Dora, et al.
Publicado: (2021)